NASDAQ: MASS908 Devices Inc Stock
$5.78-0.13 (-2.2%)
Updated Dec 16, 2025
MASS Price
$5.78
Fair Value Price
N/A
Market Cap
$209.20M
52 Week Low
$1.81
52 Week High
$9.34
P/E
-52.55x
P/B
1.53x
P/S
5.49x
PEG
N/A
Dividend Yield
N/A
Revenue
$57.64M
Earnings
-$4.13M
Gross Margin
49.2%
Operating Margin
-7.12%
Profit Margin
-7.2%
Debt to Equity
0.4
Operating Cash Flow
-$27M
Beta
1.75
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
MASS Overview
908 Devices Incorporated provides purpose-built handheld and desktop mass spectrometry devices used in life sciences research, bioprocessing, industrial biotech, and forensics. Offerings include MX908, a handheld, battery-powered device designed for the rapid analysis of gas, liquid, and solid materials of unknown identity, Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses, and ZipChip, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. 908 Devices was incorporated in 2012 and is headquartered in Boston, MA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MASS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
MASS
Ranked#49 of 102
Ranked#49 of 102
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $11.86 | A | |
| $28.95 | A | |
| $7.52 | A |
Be the first to know about important MASS news, forecast changes, insider trades & much more!
MASS News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MASS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MASS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
MASS is good value based on its book value relative to its share price (1.53x), compared to the US Medical Devices industry average (3.88x)
P/B vs Industry Valuation
MASS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more MASS due diligence checks available for Premium users.
Valuation
MASS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-52.55x
Industry
24.3x
Market
45.32x
MASS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.53x
Industry
3.88x
MASS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MASS's financial health
Profit margin
Revenue
$14.0M
Net Income
-$15.0M
Profit Margin
-107%
MASS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
MASS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$190.9M
Liabilities
$54.6M
Debt to equity
0.4
MASS's short-term assets ($144.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MASS's short-term assets ($144.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MASS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
MASS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.2M
Investing
$5.2M
Financing
-$16.0k
MASS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
MASS vs Medical Device Stocks
908 Devices Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.